Uy Geoffrey L, Rettig Michael P, Cashen Amanda F
Washington University School of Medicine, Division of Oncology, 660 S. Euclid Avenue, Campus Box 8007, St. Louis, Missouri 63110, USA.
Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797.
Stem cells harvested from peripheral blood are the most commonly used graft source in hematopoietic stem cell transplantation. While G-CSF is the most frequently used agent for stem cell mobilization, the use of G-CSF alone results in suboptimal stem cell yields in a significant proportion of patients undergoing autologous transplantation. Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4. Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF. In clinical studies of autologous stem cell transplantation, the combination of plerixafor and G-CSF allows the collection of large numbers of stem cells in fewer apheresis sessions and can salvage those who fail G-CSF mobilization alone.
从外周血中采集的干细胞是造血干细胞移植中最常用的移植物来源。虽然粒细胞集落刺激因子（G-CSF）是最常用于干细胞动员的药物，但单独使用G-CSF会导致相当一部分接受自体移植的患者干细胞产量不理想。普乐沙福（AMD3100，健赞公司）是一种双环胺分子，可拮抗趋化因子基质细胞衍生因子-1（SDF-1）与其同源受体CXCR4的结合。普乐沙福可使造血干细胞快速、可逆地动员到外周循环中，与G-CSF联合使用时有协同作用。在自体干细胞移植的临床研究中，普乐沙福与G-CSF联合使用可在较少的单采次数中采集大量干细胞，并可挽救那些单独使用G-CSF动员失败的患者。
